Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of ETH47 in Healthy Participants
NCT07055321Phase 1Completed
- Sponsor
- Ethris GmbH
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ETH47 in asthma and respiratory viral infections (9 arms), sponsored by Ethris GmbH. Primary endpoints: Number of treatment-emergent adverse events at Day 21 and Number of serious adverse events at Day 21. Started Nov 2023; status: completed.
02
Drugs
ETH47
03
Conditions
asthmarespiratory viral infections
Beyond the preview
Go deeper on NCT07055321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055321.